Navidea biopharmaceuticals announces publication of study examining use of tc99m tilmanocept for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer in australia

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer,” based on work performed at the crown princess mary cancer centre (“cpmcc”) at the university of sydney, in sydney, a
NAVB Ratings Summary
NAVB Quant Ranking